Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey - Takeaways - MDSpire

Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey

  • By

  • Niklas Schäfer

  • Elisabeth Bumes

  • Fabian Eberle

  • Viola Fox

  • Florian Gessler

  • Frank A. Giordano

  • Juergen Konczalla

  • Julia Onken

  • Malte Ottenhausen

  • Moritz Scherer

  • Matthias Schneider

  • Hartmut Vatter

  • Ulrich Herrlinger

  • Patrick Schuss

  • June 11, 2021

  • 0 min

Share

  • 1

    Multidisciplinary tumor boards (MTBs) are essential for coordinated neuro-oncology care, enhancing collaboration and adherence to treatment guidelines.

  • 2

    A nationwide survey in Germany revealed significant variability in the implementation and documentation of neuro-oncological tumor boards.

  • 3

    The COVID-19 pandemic accelerated digitalization in healthcare, presenting new opportunities for virtual participation in neuro-oncology tumor boards.

  • 4

    Of the 97 contacted neuro-oncology centers, 65 responded, with 53% being university hospitals and 5% not implementing a neuro-oncological tumor board.

  • 5

    All responding centers conducting neuro-oncological tumor boards met weekly, with 89% having established them for over three years.

Original Source(s)

Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey

  • by Niklas Schäfer, Elisabeth Bumes, Fabian Eberle, Viola Fox, Florian Gessler, Frank A. Giordano, Juergen Konczalla, Julia Onken, Malte Ottenhausen, Moritz Scherer, Matthias Schneider, Hartmut Vatter, Ulrich Herrlinger, Patrick Schuss

  • June 11, 2021

Related Content

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential